Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will ...
Compass Pathways may be the first to benefit from an accelerated approval process.
Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...
Investor's Business Daily on MSN
How Trump sent psychedelics-tied Compass Pathways and others flying
Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.
COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...
6d
Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness
Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results